PatientsVille.com LogoPatientsVille.com

Marijuana Dependence | Treatment of Marijuana Withdrawal Syndrome Using Escitalopram and Cognitive-Behavior Therapy

Marijuana Dependence research study

What is the primary objective of this study?

Recent studies have established the reliability, validity and time course of the cannabis withdrawal syndrome. This study will investigate the effects of combined treatment of Escitalopram with cognitive-behavior therapy in alleviating the symptoms of the marijuana withdrawal syndrome in regular chronic users of marijuana. We predict that combined pharmacological treatment and cognitive-behavior therapy will help patients to abstain from using using marijuana and it will alleviate their marijuana withdrawal symptoms.

Who is eligible to participate?

Inclusion Criteria: - Men and women aged 20-45 - DSM IV criteria of marijuana dependence. Exclusion Criteria: - Other drug or alcohol dependence - Bipolar disorder, schizophrenia, major depression, suicidal ideation, psychotic symptoms or violent thoughts - Physical illness including hypothyroidism, neurological disease, severe anemia, and renal failure - Past severe side effects of SSRIs.

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Marijuana Dependence

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:Escitalopram10mg/day

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

AEscitalopram + cognitive-behavior treatment

BPlacebo + cognitive-behavior therapy

Study Status

Unknown status

Start Date: December 2007

Completed Date: October 2008

Phase: N/A

Type: Interventional

Design:

Primary Outcome: Clean urine THC samples

Secondary Outcome: Questionnaire ratings of anxiety and depression and withdrawal symptoms

Study sponsors, principal investigator, and references

Principal Investigator: Miki Bloch, M.D

Lead Sponsor: Tel-Aviv Sourasky Medical Center

Collaborator:

More information:https://clinicaltrials.gov/show/NCT00598052

Discuss Celexa